Beranda › Leukemia Limfositik Kronis › Virginia
Uji klinis Leukemia Limfositik Kronis di Virginia
12 studi untuk Leukemia Limfositik Kronis mencari peserta di lokasi di Virginia.
Kota di Virginia
Teks studi resmi (Bahasa Inggris)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Health Tappahannock Hospital, Tappahannock
Menerima pesertaFase 3
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- dan 7 lainnya
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 40 hingga 75 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Ballad Health Cancer Care - Bristol, Bristol
- Ballad Health Cancer Care - Norton, Norton
- VCU Massey Cancer Center at Stony Point, Richmond
- dan 1 lainnya
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT04269902A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Virginia Commonwealth University Massey Cancer Center, Richmond
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia), Roanake
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- University of Virginia Cancer Center ( Site 5402), Charlottesville
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- University of Virginia Cancer Center ( Site 0040), Charlottesville
- Inova Schar Cancer Institute ( Site 0015), Fairfax
- Virginia Commonwealth University (VCU) Medical Center ( Site 0030), Richmond
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06136559A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- Virginia Cancer Specialists, PC, Fairfax
- Oncology & Hematology Associates of Southwest VA, Norfolk
- Virginia Oncology Associates, Norfolk
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT07221500Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Virginia Cancer Specialists, Fairfax
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT07516093A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Virginia Cancer Institute, Richmond
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT05254743A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- USO-Virginia Oncology Associates, Hampton
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT06588478A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Virginia Cancer Specialists - Fairfax /ID# 268155, Fairfax
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06428019Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.